For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
List view / Grid view
Filter the results
New approach restores epithelial function in diarrhoea and inflammatory bowel disease models...
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
Scientists discover new genes and biological pathways linked to osteoarthritis, which could help identify starting points for new medicines...
Researchers have identified a tiny hidden pocket on the NMDA receptor that could be targeted to treat strokes and seizures...
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Application note: A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
Molecular Devices announced the launch of the new SoftMax® Pro 7.1 GxP Software with complete validation tools which achieves full FDA 21 CFR Part 11 compliance in GMP/GLP labs...
Scientists in the U.S. have published their findings about the behaviour of proteins in mouse eggs, projecting possible impacts on infertility and cancer treatment.
Researchers in California have developed a method to facilitate control of nuclear pore numbers in cells. The capability is expected to glean valuable information to aid cancer treatment.
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.
14 August 2018 | By Bio-Techne
With recent advances in medicine, cellular therapies are one step closer to becoming a reality where re-programmed cells, tissues and organs can be used as therapeutic agents. This webinar discussed the journey of medical treatments from small molecule to cellular therapies...